B+
Bull case
0%
Probability
Target price
$410.00
+5.4% vs current
ELV
Elevance HealthANYSE / Health Care Equipment & Services
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
1%
Probability
Target price
$383.00
-1.6% vs current
B-
Bear case
0%
Probability
Target price
$330.00
-15.2% vs current
AI sentiment snapshot
Latest data as of 2026-05-06
Recent news sentiment (30D)
-26.5
Negative
Company
-
Unavailable
Macro
-26.5
Negative
Pulse
-
Unavailable
Sentiment proxy
+45.5
Score
AI commentary
Primary-source tone improved after the April 22, 2026 earnings release because ELV raised full-year adjusted EPS guidance and emphasized improving claims experience, but the setup still reads as cautious monitoring rather than a clean bullish re-rating. Recent headlines in the packet show moderate buzz around Medicaid margin recovery and company initiatives, yet revision depth is limited, social coverage is not provided, the peer set is only partly direct, and the deterministic prior remains neutral with slightly negative expected returns and mid-level uncertainty. Net sentiment is therefore mildly improved but tentative.
RankAlpha Sentiment Codex - 2026-05-06
Open full AI memoEvidence flagged
peer set is too generic or lacks enough direct operating comparators; memo remains a monitoring view with limited forward evidence and should not be standard-conviction
Impact
tentative
Confidence
-
AI events
2026-06-30catalystQ1 beat and raised 2026 adjusted EPS need a clean Q2 follow-throughMedium impact
Elevance reported 1Q26 adjusted EPS of $12.58, raised FY26 adjusted EPS guidance to at least $26.75, and cited improving claims experience, disciplined pricing, and stronger visibility; the near-term question is whether that improved medical-cost trend holds into the next reporting window rather than proving to be a one-quarter reset [#8-K-2026-04-22].
2026-12-31eventCMS notice resolution remains the main overhangMedium impact
Management accrued $935 million for its current best estimate of potential exposure tied to the CMS notice and said FY26 cash-flow guidance already includes potential cash payments; any clarity that caps, stretches, or reduces the ultimate impact could materially change sentiment, while adverse updates would likely pressure the multiple [#8-K-2026-04-22].
2027-03-31catalystCarelon growth and cost actions can offset Medicaid pressure if execution stays consistentHigh impact
Company materials point to Carelon Services and CarelonRx growth, targeted medical-cost actions, AI-enabled operating leverage, and a stated goal to return to at least 12% adjusted EPS growth in 2027; that is the core medium-term upside path, but it depends on sustained execution against Medicaid cost pressure and membership runoff [#8-K-2026-04-22].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-06 • Updated nightlySource: Internal modelMethodology